The phase I trial of CB7630, an orally active inhibitor of the steroidal enzyme 17alpha-hydroxylase/C17,20 lyase, will be conducted at the University of California San Francisco Comprehensive Cancer Center with Dr Charles Ryan, assistant clinical professor of medicine, as the principal investigator of the trial.
The study is an open label, dose escalating study to evaluate the safety and efficacy of CB7630 administered daily to patients with chemotherapy-naive hormone refractory prostate cancer (HRPC) with a rising PSA (prostate specific antigen) despite hormonal therapy.
“We are pleased to be able to begin enrolling patients in this phase I study,” said Dr Ryan. “Inhibition of 17alpha-hydroxylase/C17,20 lyase represents a promising new approach to the treatment of HRPC and CB7630 may be able to offer clinical benefit to HRPC patients.”